New Approach Methodologies Market Outlook 2026–2036: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Organ-on-a-Chip, Organoids, In Silico Toxicology and Complex In Vitro Models under the FDA Roadmap, NIH Funding and the EU Phase-Out of Animal Testing — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how new approach methodologies (NAMs) — organ-on-a-chip systems, organoids and complex in vitro models, in silico and AI toxicology, human tissue assays and read-across — will replace animal studies in drug and chemical safety assessment over the next ten years, now that regulators have changed the rules. The FDA Modernization Act 2.0 of December 2022 removed the statutory requirement for animal tests before human trials; the FDA's April 2025 roadmap set a stepwise plan starting with monoclonal antibodies, followed by December 2025 draft guidance on streamlined nonclinical safety studies for antibodies and, in March 2026, general draft guidance under which sponsors may submit NAM data in place of animal studies without prior validation, judged on relevance, reliability and fitness for the decision. The FDA's April 2026 update reported its first-year goals met, including horseshoe-crab endotoxin guidance expected to spare more than a million animals a year, a searchable database of accepted alternatives and its first qualified AI-based drug development tool; the ISTAND qualification programme became permanent after accepting eight submissions including Emulate's Liver-Chip S1. The NIH committed more than USD 150 million to human-based methods in March 2026 under Complement-ARIE, with USD 20 million for a validation and qualification network, and the FDA Modernization Act 3.0 passed both chambers of Congress in 2026. In Europe, the Commission published its roadmap to phase out animal testing in chemical safety assessment on 1 June 2026, backed by ECHA, against about 500,000 animal procedures a year. Yet organ-chip venture funding fell 78% in 2025 to USD 12.6 million across three rounds. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2036.

It is a focused 104-page decision brief for pharmaceutical and biotechnology companies, contract research organisations, organ-chip and organoid companies, chemical and consumer-product companies, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which methods replace which animal studies first, how regulatory acceptance and validation set the pace, and who captures value as safety assessment moves from animals to human-relevant models.

New approach methodologies replace the animal with human biology and computation. Organ-on-a-chip devices line microfluidic channels with human liver, kidney, lung, gut, heart or bone-marrow cells under flow and mechanical cues so that tissues behave as they do in the body — Emulate's Liver-Chip S1 models drug-induced liver injury and its AVA instrument runs 96 chip emulations in parallel; CN Bio, MIMETAS, TissUse, InSphero, Hesperos, Vivodyne and Quris build single- and multi-organ systems. Organoids grown from stem cells reproduce organ structure for toxicity and efficacy testing. In silico tools — quantitative structure–activity models, read-across, physiologically based pharmacokinetic models and AI predictors — estimate toxicity and exposure from chemistry and prior data, and the FDA has now qualified its first AI-based drug development tool. Human tissue and cell assays run on robotic screening complete the toolkit.

Regulation has moved from permission to encouragement. The FDA's March 2026 guidance sets four principles — define the regulatory use, show relevance to human biology, establish technical reliability and confirm fitness for the decision — and removes the need for prior validation or qualification, settling evidence expectations through pre-submission meetings and precedent; the December 2025 antibody guidance targets the non-human primate studies that are the most costly and contested; ISTAND offers a formal qualification path; and the NIH is paying for validation through a USD 20 million network with the Foundation for the NIH and a reduction-to-practice challenge with FDA and EPA. The EU roadmap moves chemical safety under REACH, pesticides and biocides toward NAM-first assessment, with ECHA, EMA and EFSA charged with implementation. The science is pushed by a hard fact: more than 90% of drugs that look safe and effective in animals fail in humans.

The constraints are validation, context of use, commercial scale and capital. Each method must be shown fit for a defined decision, and regulators still expect animal data for novel mechanisms, complex biologics and first-in-class therapies; organ chips are run at small scale in discovery labs rather than as regulated nonclinical packages; CROs must rebuild workflows and staff; and the organ-chip sector raised only USD 12.6 million of venture capital in 2025, 78% less than 2024, despite the policy tailwind. The decade's question is how fast pharma and CROs convert regulatory permission into NAM-based submissions.

The new approach methodologies market — organ-on-a-chip and microphysiological systems, organoid and complex in vitro models and consumables, in silico and AI toxicology software, NAM-based CRO and testing services and validation programmes, excluding conventional cell-culture and animal-study revenue — is estimated at USD 1.8–2.4 billion in 2026, led by organoid and complex in vitro models in pharma discovery, in silico and read-across tools in chemical and drug safety, organ-chip instruments and consumables and early NAM-based CRO services. Meticulous Next™ expects it to reach USD 12–16 billion by 2036, an indicative CAGR of 20–22%. Growth is driven by replacement of non-human primate studies for monoclonal antibodies from 2026, by general NAM acceptance in FDA and EMA submissions, by EU chemical safety phase-out under REACH, pesticides and biocides rules, by NIH and EU validation funding, by CROs converting nonclinical programmes and by qualified organ chips and AI tools entering defined contexts of use. The forecast is sensitive to the pace of qualification and to pharma conservatism in pivotal studies. The United States leads on regulatory change, qualification and organ-chip companies; Europe leads on chemical safety phase-out and in vitro model companies; the United Kingdom contributes CN Bio and MHRA alignment; Japan and Korea adopt through regulatory convergence; antibodies, hepatotoxicity, chemicals and cosmetics lead the applications.

The base case assumes NAM-based antibody packages become routine by 2028, the first organ-chip and AI qualifications by 2027–2028, FDA Modernization Act 3.0 enacted in 2026 and EU implementation from 2027. An accelerated case adds fast qualification, strong NIH and EU validation output and CRO conversion, bringing the inflection to 2028 and lifting the 2036 value to the top of the range. A delayed case assumes slow qualification, pharma conservatism in pivotal studies and funding drought for organ-chip companies, pushing the inflection to 2031 and confining NAMs to discovery and chemical screening.

Growth drivers

• Regulatory change: FDA Modernization Act 2.0 and 3.0, the April 2025 roadmap, December 2025 antibody guidance and March 2026 general NAM guidance; EU chemicals roadmap of June 2026.
• Public funding: NIH's USD 150 million Complement-ARIE commitment, ORIVA, the USD 20 million validation network and the FDA–EPA reduction-to-practice challenge.
• Science and cost: more than 90% of animal-validated drugs fail in humans; non-human primate studies are the most expensive and contested.
• Animal welfare and supply: horseshoe-crab guidance sparing a million animals a year, NHP supply constraints and public pressure including 1.2 million EU citizens' signatures.

Enablers

• Qualification pathways: ISTAND permanent, FDA database of accepted alternatives, pre-submission consultation.
• Organ-chip throughput: 96-chip instruments, robotic labs and multi-organ systems.
• Validation networks and ring trials such as TissUse's Liver Ring Trial and the FNIH network.
• AI and in silico tools with the first FDA-qualified AI drug development tool.

Restraints and barriers

• Context-of-use limits: animal data still expected for novel mechanisms, complex biologics and first-in-class therapies.
• Validation and qualification time for each method and endpoint.
• Capital: organ-chip venture funding of USD 12.6 million in 2025, down 78%.
• CRO and pharma workflow inertia and liability concerns in pivotal studies.

Five converging forces will determine how fast, and how far, NAMs replace animal testing: (1) regulatory guidance and statute in the United States and Europe; (2) qualification and validation output; (3) pharma and CRO conversion of nonclinical programmes; (4) organ-chip, organoid and AI capability and throughput; and (5) funding and capital for method developers. The brief assesses each force for direction, speed and confidence.

The key players operating in new approach methodologies include Emulate, Inc., CN Bio Innovations Ltd, MIMETAS B.V., TissUse GmbH, InSphero AG, Hesperos, Inc., Vivodyne, Inc., Quris-AI (Numa Biosciences), Dynamic42 GmbH, AlveoliX AG, BiomimX S.r.l., STEMCELL Technologies Inc., Molecular Devices, LLC (Danaher Corporation), Corning Incorporated, Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Lonza Group AG, Charles River Laboratories International, Inc., Labcorp Holdings Inc., Inotiv, Inc., WuXi AppTec Co., Ltd., Evotec SE, Certara, Inc., Simulations Plus, Inc., Lhasa Limited, Instem plc, Schrödinger, Inc., VeriSIM Life, Inc., Hurel Corporation, Tempo Bioscience, Inc., Xellar, Inc., Unilever PLC, L'Oréal S.A., Procter & Gamble Company, BASF SE, Eli Lilly and Company, Roche Holding AG, AstraZeneca PLC, GSK plc, the Foundation for the NIH, the European Chemicals Agency and the Johns Hopkins Center for Alternatives to Animal Testing. The brief profiles representative players in each archetype and assesses which are positioned to supply NAM-based assessment at scale.

The competitive landscape is forming around six archetypes. Organ-on-a-chip and microphysiological system companies. Organoid, 3D cell model and consumables suppliers. In silico, AI and modelling software providers. Contract research organisations converting nonclinical programmes. Pharma, chemical and consumer-product sponsors. Regulators, funders and validation bodies. Competitive intensity is moderate in 2026 and is expected to rise around qualification and CRO conversion through 2030.

Where value migrates.

In 2026 value sits in organoid and complex in vitro models in discovery, in silico tools in chemical and drug safety, organ-chip instruments and consumables and early NAM-based CRO services. By 2029 it moves to NAM-based antibody safety packages, qualified organ chips and AI tools in defined contexts of use, EU NAM-first chemical dossiers and CRO programmes. By 2036 it settles in organ-chip and model companies with qualified methods and services, CROs that converted early, in silico and AI toxicology providers, validation networks and sponsors that cut development time. Animal-study capacity, especially non-human primate work, and unqualified methods lose share.

Policy capital leads private capital: NIH's USD 150 million, the USD 20 million validation network and USD 7 million challenge, FDA's qualification infrastructure and the EU roadmap, while organ-chip venture funding fell to USD 12.6 million in 2025 and Vivodyne's USD 40 million round stood out. Industry investment shows in throughput — Emulate's 96-chip AVA, robotic tissue labs — and in CRO positioning. Patent and research activity is concentrated in multi-organ systems, immune-competent chips, organoid standardisation, AI toxicology and integration of in vitro and in silico data. The brief tracks four indicators: ISTAND qualifications, NAM-based antibody submissions and approvals, EU implementation guidance under REACH and CRO NAM programme launches.

The United States leads on regulatory change, qualification, funding and organ-chip companies; Europe leads on chemical safety phase-out and in vitro model companies in the Netherlands, Germany and Switzerland; the United Kingdom contributes CN Bio and MHRA alignment; Japan and Korea adopt through convergence. Antibody safety, hepatotoxicity, chemicals and cosmetics are the first applications.